MARQIBO
Total Payments
$192,758
Transactions
98
Doctors
79
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $84,749 | 25 | 20 |
| 2021 | $108,008 | 73 | 60 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $191,298 | 8 | 99.2% |
| Food and Beverage | $1,455 | 89 | 0.8% |
| Education | $5.00 | 1 | 0.0% |
Payments by Type
Research
$191,298
8 transactions
General
$1,460
90 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A multi-center, open-label phase 1b/2 study of inotuzumab ozogamicin and vincristine sulfate liposome in adult patients with relapsed/refractory B lineage acute lymphoblastic leukemia (B-ALL) | Acrotech Biopharma LLC | $76,275 | 0 |
| A phase 2 single arm multicenter trail to evalaute the efficacy of the bite antibody Blincyto and vincristine sulfate liposmal injection Marqibo in adult subjects with relapsed refracatory philadelphia negative cd19 acute lymphoblastic leukemia | Acrotech Biopharma LLC | $63,732 | 0 |
| T2012-002 Protocol Amendment #4 version Date 03-Dec-2021 A pilot study of Vincristine Sulfate Liposome injection(Marquibo) in combination with chemotherapy for children, adolescents and young adults with relapse of acute lymphoblastic leukemia IND 128316 | Acrotech Biopharma LLC | $33,750 | 0 |
| A Phase I Dose-Escalation Study of Vincristine Sulfate Liposome Injection (Marqibo) in Combination with Bendamustine and Rituximab (BRiM) in Indolent non-Hodgkin Lymphoma (IIS-MAR-003) | Acrotech Biopharma LLC | $9,358 | 0 |
| Lead-in and Phase II Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine* (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma | Acrotech Biopharma LLC | $8,183 | 0 |
Top Doctors Receiving Payments for MARQIBO
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $191,298 | 8 |
| , MD | Diagnostic Radiology | Houston, TX | $38.47 | 2 |
| , M. D | Hematology & Oncology | Houston, TX | $38.47 | 2 |
| , M.D | Internal Medicine | Houston, TX | $38.47 | 2 |
| , FNP | Family | Memphis, TN | $35.08 | 2 |
| , M.D | Hematology & Oncology | Memphis, TN | $35.08 | 2 |
| , MD | Internal Medicine | Paducah, KY | $34.36 | 2 |
| , APRN | Registered Nurse | Paducah, KY | $34.36 | 2 |
| , M.D | Hematology & Oncology | Elizabethtown, KY | $32.79 | 2 |
| , M.D | Hematology & Oncology | Elizabethtown, KY | $32.79 | 2 |
| , M.D | Medical Oncology | Naples, FL | $30.00 | 2 |
| , MD | Hematology & Oncology | Owensboro, KY | $29.52 | 2 |
| , MD | Hematology & Oncology | New Albany, IN | $25.63 | 1 |
| , M.D | Medical Oncology | Tinley Park, IL | $21.74 | 1 |
| , M.D | Hematology & Oncology | Memphis, TN | $20.90 | 1 |
| , MD, PHD | Hematology & Oncology | Memphis, TN | $20.90 | 1 |
| , MD | Pediatric Hematology-Oncology | Sacramento, CA | $20.03 | 1 |
| , MD | Pediatric Hematology-Oncology | Sacramento, CA | $20.03 | 1 |
| , MD | Hematology & Oncology | Baton Rouge, LA | $18.78 | 1 |
| Malorie Irwin | Family | Baton Rouge, LA | $18.78 | 1 |
| , NP | Family | Knoxville, TN | $18.55 | 1 |
| , FNP | Family | Corinth, MS | $18.33 | 1 |
| , M.D | Hematology & Oncology | Germantown, TN | $18.33 | 1 |
| , CFNP | Family | Corinth, MS | $18.33 | 1 |
| , M.D | Radiation Oncology | Port Arthur, TX | $18.33 | 1 |
Ad
Manufacturing Companies
- Acrotech Biopharma LLC $192,758
Product Information
- Type Drug
- Total Payments $192,758
- Total Doctors 79
- Transactions 98
About MARQIBO
MARQIBO is a drug associated with $192,758 in payments to 79 healthcare providers, recorded across 98 transactions in the CMS Open Payments database. The primary manufacturer is Acrotech Biopharma LLC.
Payment data is available from 2021 to 2022. In 2022, $84,749 was paid across 25 transactions to 20 doctors.
The most common payment nature for MARQIBO is "Unspecified" ($191,298, 99.2% of total).
MARQIBO is associated with 5 research studies, including "A multi-center, open-label phase 1b/2 study of inotuzumab ozogamicin and vincristine sulfate liposome in adult patients with relapsed/refractory B lineage acute lymphoblastic leukemia (B-ALL)" ($76,275).